柳叶刀 | 乌帕替尼可使白癜风患者获得有临床意义的面部及全身复色

Declaration of interests

TP is a consultant for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Calypso, Galderma, Incyte Corporation, Janssen, Eli Lilly, Novartis, Pfizer, Roivant, UCB, and VYNE Therapeutics. He has received grants, honoraria, or both from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme/ Sanofi, GlaxoSmithKline, Incyte Corporation, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Roivant, Sun Pharmaceuticals, Takeda, UCB, and VYNE Therapeutics. He is the cofounder of NIKAIA Pharmaceuticals and founder of SUNLUTION; and has patents on WNT agonists or GSK3b antagonist for repigmentation of vitiligo and the use of CXCR3B blockers in vitiligo. VHP has served as an advisor, consultant, and/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, Knight Therapeutics, LEO Pharma, Lilly, Medexus, Nia Health, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharmaceuticals, Tribute, and UCB. He has also served as an investigator for AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Galderma, Incyte, J&J Innovative Medicine, Janssen, Leo Pharma, Lilly, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, Q32 Bio, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, UCB, and VYNE Therapeutics; and received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. RKS has served as a consultant or speaker for Amgen, Burt’s Bees, Sanofi, Bristol Myers Squibb, Arbonne, Trace Minerals, Codex Labs, Pfizer, Phothera, Almirall, Nutraceutical Wellness, Lilly, Galderma, Incyte, Novartis, Arcutis, Janssen, AbbVie, Leo Pharma, UCB, Sun Pharmaceuticals, and Regeneron Pharmaceuticals. KE is a consultant for AbbVie, Incyte Corporation, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. NvG has received grants from and/or is a consultant and/or investigator for AbbVie, Incyte, Merck/MSD, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, Takeda, Teva, and Sun Pharmaceuticals; and is chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology (EADV). IH is a consultant for AbbVie, Almirall, Avita, Boehringer Ingelheim, Galderma, Incyte, Janssen, Novartis, Pfizer, Merck, UCB, Lilly, and Teva. He is an investigator for AbbVie, Avita, Incyte, Lenicura, L’Oréal/La Roche-Posay, Merck, Takeda, Teva, and Pfizer; and is a board member and former President of the Hidradenitis Suppurativa Foundation and Global Vitiligo Foundation. AGP has served as an investigator for Avita, Clinuvel, and Incyte; as a consultant for AbbVie, Avita, Boehringer Ingelheim, Incyte, Lilly, Pfizer, Sun Pharmaceuticals, Vimela, Vyne, and WCG; and is a shareholder for Tara Medical. DR has served as a consultant, spoken for, or conducted trials for the following companies: AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Dualitas, Edesa Biotech, EMD Serono, Forte Biosciences, Galderma, Incyte, Inmagene, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, Takeda, UCB, VielaBio, and Zura Bio. LX is a consultant for AbbVie, Galderma, Merz, Solta, Skinceutical, Beiersdof, P&G, Botanee, JAKA, and Unilever. TS has consulted for, spoken for, or collaborated on research with AbbVie, Pfizer, J-TEC, Maruho, and Pola. He is the President of the Japanese Society of Vitiligo. SD has served as a consultant and/or investigator for AbbVie as well as Pfizer, Incyte, Eli Lilly, Galderma, L’Oreal, Alumis, and Apogee and has held multiple leadership roles in dermatology and health care. MR has received grants and/or honoraria from and/or served as a consultant, spoken for, or conducted trials for the following companies: AbbVie, LEO Pharma, Dermavant, Incyte, Janssen, Pfizer, Dren Bio, ITN, Elixiron, Sanofi, Biogen, Incyte, Abeona Therapeutics, Edesa Biotech, Atlas Venture, Inzen, ROME Therapeutics, Almirall, Medicxi, Related Sciences, and VisualDx. SS, IF, XH, XW, MW, YY, AMS, HSC, HDT, SP, and BJS are employees of AbbVie and may own stocks or stock options. AMS is a co-inventor on AbbVie patents. JS has received grants and/or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Incyte, LEO Pharma, Lilly, Novartis, Pfizer, Pierre Fabre, Sanofi, and Silab; and has a patent on MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder and three-dimensional model of depigmenting disorder.

点击阅读原文，查阅论文原文

关注柳叶刀服务号，探索更多科研服务！